Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial
===============================================================================================================================================================================================================

* Robert J Motzer
* Bernard Escudier
* David F McDermott
* Osvaldo Arén Frontera
* Bohuslav Melichar
* Thomas Powles
* Frede Donskov
* Elizabeth R Plimack
* Philippe Barthélémy
* Hans J Hammers
* Saby George
* Viktor Grünwald
* Camillo Porta
* Victoria Neiman
* Alain Ravaud
* Toni K Choueiri
* Brian I Rini
* Pamela Salman
* Christian K Kollmannsberger
* Scott S Tykodi
* Marc-Oliver Grimm
* Howard Gurney
* Raya Leibowitz-Amit
* Poul F Geertsen
* Asim Amin
* Yoshihiko Tomita
* M Brent McHenry
* Shruti Shally Saggi
* Nizar M Tannir